Substipharm Développement

Substipharm is a French pharmaceutical company specializing in the development and commercialization of generic and niche medicinal products. Founded in 1996, the company focuses on creating high-value dossiers for complex generics and specialty drugs across various therapeutic areas, including the central nervous system, oncology, and infectious diseases. Substipharm operates through a business model that includes out-licensing its developed dossiers to international partners and direct commercialization in the French market. The company is known for its expertise in navigating complex regulatory environments and managing the full lifecycle of pharmaceutical products from development to market. In 2021, Substipharm was acquired by Ethypharm, a leading European specialty pharmaceutical group, to strengthen its portfolio and geographic reach. Today, it continues to operate as a key component of Ethypharm's growth strategy in the specialty off-patent market.